Britain and America have announced a significant bilateral deal that will ensure no levies on British medicine shipments entering the US market.
Agreement Details of the Pact
In exchange for the tariff guarantee, the UK has agreed to raise expenditure on medicines through the NHS. This move ensures that import taxes on these vital exports will be held at nothing for a duration of the next three years.
This development is in response to earlier statements to hike tariffs on branded pharmaceutical products, with potential rates discussed as high as one hundred percent.
"This deal between the United Kingdom reinforces the international landscape for cutting-edge drugs and brings much-needed fairness to transatlantic drug exports," a release noted.
Trade Importance
Medicines are one of the UK's biggest export categories to the America, which is easily the primary destination for large companies like GSK and AstraZeneca.
Export figures reveal that in the 12 months prior to the third quarter, the UK sold drugs worth billions to the US. This value accounted for nearly one-fifth of British export trade in that span.
"This deal secures jobs, increases capital expenditure and facilitates the UK to establish itself as a worldwide center for medical research," the Business and Trade Secretary commented.
Detailed NHS Changes
The agreement entails several notable commitments from the United Kingdom:
- Revised Affordability Limit: The UK will increase the affordability limit at which it considers new medicines to be too expensive by twenty-five percent.
- Increased NHS Spending: There is a target to raise overall health service expenditure on medicines from 0.3 percent of Gross Domestic Product to 0.6% over the following ten-year period.
- Rebate Cap: The percentage drug companies must pay back to the NHS to control costs will be capped at 15%. Previously, rebates were more than twenty percent.
Broader Context
The pact comes amid a ongoing dispute between the drug companies and the UK government over spending levels and NHS adoption.
These tensions were intensified by claims that US consumers were charged a premium for the same drugs than consumers in the UK and Europe.
Over the last 18 months, several large drug company projects in the UK have been delayed or cancelled, while substantial funding commitments have been pledged toward projects in the United States.
A senior figure stated that the NHS needed to spend more on treatments, noting that its budget allocation on drugs had declined as a percentage of its overall budget over the previous ten-year period.
